Table 1 Clinical demographics.
| Variables | TMZ group (n = 136) | Control group (n = 130) | p Value |
|---|---|---|---|
| Mean (SD) age (years) | 68 (12) | 53 (13) | <0.001 |
| Sex, male, n (%) | 98 (72) | 92 (71) | 0.8 |
| Renal insufficiency, n (%) | 23 (13) | 19 (15) | 0.6 |
| Angina class,* n (%) | |||
| 1 + 2 | 53 (39) + 36 (27) | 68 (52) + 42 (32) | <0.01 |
| 3 + 4 | 22 (16) + 25 (18) | 12 (9) + 8 (6) | <0.001 |
| Risk factors, n (%) | |||
| Smoking (past or current) | 79 (58) | 72 (55) | 0.65 |
| Diabetes mellitus | 59 (43) | 23 (17) | <0.001 |
| Hypercholesterolaemia | 56 (41) | 52 (40) | 0.84 |
| Hypertension | 55 (40) | 42 (31) | 0.13 |
| Family history | 14 (10) | 16 (12) | 0.6 |
| Mean (SD) BMI (kg/m2) | 27.2 (2.3) | 21.6 (2.9) | <0.001 |
| Medication, n (%) | |||
| β Blockers | 39 (28) | 41 (32) | 0.44 |
| Calcium antagonist | 42 (31) | 43 (33) | 0.7 |
| Aspirin | 76 (56) | 75 (58) | 0.76 |
| Clopidogrel | 24 (18) | 25 (19) | 0.74 |
| Statin | 42 (31) | 39 (30) | 0.88 |
| Insulin | 23 (17) | 29 (22) | 0.27 |
| ACE inhibitors | 43 (31) | 36 (28) | 0.57 |
BMI, body mass index; TMZ, trimetazidine.
*According to the Canadian classification.